Stocks Grind Higher on Good Fundamentals: Stock Market Today The stock market is a forward-looking mechanism, and what it sees at the bottom line carries greater weight right now than geopolitical uncertainty. Kiplinger · May 27
Why Wall Street Thinks This Dividend Stock Could Jump 30% Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility. Barchart · May 22
S&P 500 Hits New High on Apple Earnings: Stock Market Today Apple rounded out a big week of mega-cap earnings on a high note, sending two of the three main equity indexes to new highs on Friday. Kiplinger · May 1
What to Expect From Amgen's Next Quarterly Earnings Report Amgen is scheduled to report its first-quarter results next week, and analysts expect a single-digit earnings dip. Barchart · Apr 20
Dow Leads in Mixed Session on Amgen Earnings: Stock Market Today The rest of Wall Street struggled as Advanced Micro Devices earnings caused a chip-stock sell-off. Kiplinger · Feb 4
Nasdaq Futures Climb on Blowout Palantir Results March Nasdaq 100 E-Mini futures (NQH26) are trending up +0.41% this morning as forecast-beating quarterly results and guidance from Palantir Technologies boosted sentiment. Barchart · Feb 3
Amgen Stock: Is Wall Street Bullish or Bearish? Are Wall Street analysts bullish or bearish on Amgen’s stock prior to its Q4 earnings release? Barchart · Feb 2
Dow Hits New High Then Falls 466 Points: Stock Market Today The Nasdaq Composite, with a little help from tech's friends, rises to within 300 points of its own new all-time high. Kiplinger · Jan 7
6 Dividend Stocks Retirees Are Quietly Buying for Steady Income For retirees, dividend stocks can offer the best of both worlds. The most obvious is a steady income stream, one that often increases over time. The other is the potential for capital appreciation,... GOBankingRates · Dec 18, 2025
3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%. MarketBeat · Dec 16, 2025
Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday. Benzinga · Dec 3, 2025
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry. MarketBeat · Dec 1, 2025
Amgen Stock: New All-Time Highs Ahead After Earnings Beat Amgen stock jumps after a strong beat-and-raise quarter, pushing shares near split-adjusted all-time highs and signaling more upside ahead MarketBeat · Nov 7, 2025
Marjorie Taylor Greene Already Made Double-Digit Gains From Amazon; Cardinal Health Trades Days Before Earnings Beat Greene's investments in Amazon and Cardinal Health on 24 October are up 11.5% and 21.5%, respectively, following the companies' strong Q3 earnings reports. International Business Times UK · Nov 6, 2025
Barchart · Oct 31, 2025 Amgen Stock: Analyst Estimates & Ratings Amgen stock has been underperforming the broader market over the past year, and analysts are adopting a cautiously bullish stance.
Barchart · Oct 25, 2025 The Saturday Spread: Using Data Science to Find Call Spreads Priced in Your Favor It’s already difficult enough when you step into the world of options. Here’s how to even up the odds against the big dogs.
Barchart · Oct 10, 2025 Here's What to Expect From Amgen’s Next Earnings Report Amgen is scheduled to report its third-quarter earnings next month, and analysts forecast a modest single-digit decline in profits.
Benzinga · Oct 6, 2025 Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices Amgen Inc. (NASDAQ:AMGN) on Monday launched AmgenNow, a new direct-to-patient program starting with Repatha (evolucumab).
Kiplinger · Oct 2, 2025 The Best Biotech ETFs to Buy Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.
Barchart · Sep 27, 2025 The Saturday Spread: 3 Beaten-Down Stocks Making a Statistical Case for a Comeback Here’s an innovative approach to deciphering which red-stained stocks are actually worth a look for bullish contrarians.
Benzinga · Sep 26, 2025 Amgen Expands US Manufacturing Network Amid New Tariff Policy Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.
Benzinga · Sep 22, 2025 European Advisory Panel Recommends Two AstraZeneca Drugs For Approval AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc.'s (NASDAQ:AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Benzinga · Sep 19, 2025 EMA Backs Amgen Drug For Rare Autoimmune Disorder The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD).
Benzinga · Sep 9, 2025 Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday.
Benzinga · Sep 4, 2025 Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed.